Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
Explore this paper's citation graph
Summary
The analyses suggest that the beneficial effect of simvastatin in individual patients in 4S was determined mainly by the magnitude of the change in LDL cholesterol, and they are consistent with current guidelines that emphasize aggressive reduction of this lipid in CHD patients.
- Type
- article
- Published
- 1998-04-21
- Cited by
- 661
- References
- 32
- Access
- Open access
- OpenAlex
- https://openalex.org/W2011277263
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:52858952
Keywords
Medicine, Simvastatin, Internal medicine, Cardiology, Coronary heart disease
References
- Lowering cholesterol in high-risk individuals and populations
- Logical and statistical fallacies in the use of Cox regression models.
- Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery.
- Lipids and risk of coronary heart disease. The Framingham Study.
- The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
- Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
- Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
- When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction.
- Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort.
- The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
- Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.
- Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease.
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
- Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study.
- Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
- By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
- Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.
Cited by
- Vitamin E and vascular homeostasis: implications for atherosclerosis
- Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.
- Serum Lipid Profile Constituents as Markers of Cardiovascular Morbidity in Patients on Chronic Hemodialysis
- Use of cardiovascular medications in the elderly.
- Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors.
- Atherosclerotic Cardiovascular Disease Risk in the HAART-Treated HIV-1 Population
- Less than 50% of variation in HDL cholesterol between and within individuals, is explained by established predictors.
- HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.
- Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
- Therapie mit CSE-Hemmern — mehr als Lipidsenkung?
- Lipid pattern in middle-aged inhabitants of the Lower Silesian region of Poland. The PURE Poland sub-study.
- Genome-Wide Association Studies: Progress in Identifying Genetic Biomarkers in Common, Complex Diseases
- Statin-paraoxonase Interactions During Statin Treatment
- Pharmacotherapy of Dyslipidemia
- Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging.
- Efficacy and Tolerability of Fluvastatin in a Titration Dosage Regimen in Hyperlipidaemic Patients
- Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
- Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials
- Novel Lipids Targets in the Era of Metabolic Syndrome
- Pleiotropic Effects of Statins
Related papers
- The treating observation and C-reactive protein detection in elderly coronary heart disease by simvastatin
- Prevention of new occurred atrial fibrillation in coronary heart disease patients by Simvastatin
- Effects of Simvastatin on Plasma Levels of IL-6 and IL-10 in Patients with Coronary Heart Disease
- The effect of simvastatin on C reactive protein in patients with coronary heart disease
- Effectiveness and safety of simvastatin in the treatment of coronary heart disease in patients with dyslipidemia
- Clinical Analysis of Simvastatin on the Advanced Aged Patients with Coronary Heart Disease
- The impact of cigarette smoking on the pleiotropic effects of simvastatin in the coronary heart disease patients
- The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease.